A. Insa

发表

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

E. Felip, F. de Marinis, G. Altavilla, 2012, The Lancet. Oncology.

OA13.05 NADIM Study: Updated Clinical Research and Outcomes

N. Viñolas, B. Massuti, M. Provencio, 2019, Journal of Thoracic Oncology.

Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients

Ana Lluch, I. Marugán, F. Prósper, 1999, Breast Cancer Research and Treatment.

In the literature: February 2019

A. Cervantes, A. Insa, V. Gambardella, 2019, ESMO Open.

Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

E. Felip, F. de Marinis, M. Taron, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?

R. Franco, G. Vicidomini, C. D. Della Corte, 2021, Critical reviews in oncology/hematology.

Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer

A. Lluch, J. López-Guerrero, R. Botella-Estrada, 2009, Melanoma research.

Heriditary cancer syndromes: role ofprevention and screening

I. Chirivella, A. Insa, S. Roselló, 2008 .

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First‐Line Platinum‐Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS‐lung Trial

H. Groen, V. Torri, U. Dafni, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients

A. Insa, R. Abellán, P. Martorell, 2017, Clinical lung cancer.

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

E. Felip, F. de Marinis, L. Paz-Ares, 2015, JAMA oncology.

Molecular genetic analysis of HLA-DR and -DQ alleles in Spanish patients with melanoma.

E. Nagore, C. Guillen, A. Insa, 2002, Acta dermato-venereologica.

Antineoplastic Therapy—Induced Palmar Plantar Erythrodysesthesia (‘Hand-Foot’) Syndrome

E. Nagore, O. Sanmartı́n, A. Insa, 2000, American journal of clinical dermatology.

Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.

R. Rosell, M. Sánchez-Ronco, B. Massuti, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of chemotherapy dose-related factors on survival in breast cancer patients treated with adjuvant anthracycline-based chemotherapy.

I. Chirivella, A. Lluch, A. Bosch, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment.

N. Viñolas, B. Massuti, M. Provencio, 2019, Journal of Clinical Oncology.

Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.

B. Massuti, V. Calvo, D. Rodríguez-Abreu, 2018 .

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Javier M. Martín-López, N. Viñolas, B. Massuti, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

N. Viñolas, B. Massuti, V. Calvo, 2022, Journal for ImmunoTherapy of Cancer.

Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR in-frame deletions of exon 19 according to the size of the deletion.

R. Rosell, M. Taron, C. Camps, 2010 .

Basal cell carcinoma with distant multiple metastases to the vertebral column

A. Insa, E. Jordá, C. Monteagudo, 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.

Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis

R. Botella-Estrada, E. Nagore, A. Insa, 2005, Melanoma research.

Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.

A. Tafreshi, R. Govindan, Xin Huang, 2022, Clinical lung cancer.

Screening for epidermal growth factor receptor mutations in lung cancer.

Mariano Provencio, Miguel Angel Molina, Bartomeu Massuti, 2009, The New England journal of medicine.

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

J. Mate, C. Sawyers, A. Ariza, 2011, Clinical Cancer Research.

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)

N. Reguart, M. Provencio, R. García-Campelo, 2018, Clinical and Translational Oncology.

Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

V. Escudero-Vilaplana, A. Insa, I. Sullivan, 2023, BMC Pulmonary Medicine.

CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC.

Kwok-Kin Wong, F. Al-Shahrour, P. Janne, 2019, Cancer research.

ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort.

E. Esteban, N. Reguart, B. Massuti, 2020, Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia.

Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma

J. Bosch-Barrera, J. Sánchez, T. Morán, 2021, Clinical and Translational Oncology.

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.

I. Wistuba, N. Viñolas, B. Massuti, 2020, The Lancet. Oncology.

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).

N. Viñolas, B. Massuti, M. Provencio, 2019, Lung cancer.

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.

M. Hellmich, J. Franklin, E. Smit, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.

J. Bosch-Barrera, R. Rosell, N. Reguart, 2017, Lung cancer.

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

R. Rosell, M. Taron, N. Reguart, 2014, Lung Cancer.

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

I. Wistuba, N. Viñolas, B. Massuti, 2021, Clinical Cancer Research.

A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study

E. Felip, A. Insa, D. Isla, 2022, Clinical and Translational Oncology.

Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early‐onset breast cancer: Identification of three novel pathogenic mutations

J. Garcia-conde, I. Chirivella, Á. Carracedo, 2003, Human mutation.

Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer.

R. Rosell, M. Taron, M. Sánchez-Ronco, 2004, Clinical lung cancer.

PL03.12 Progression Free Survival and Overall Survival in NADIM II Study

J. Bosch-Barrera, M. Provencio, C. Camps, 2022, Journal of Thoracic Oncology.

MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial

J. Bosch-Barrera, M. Provencio, C. Camps, 2022, Journal of Thoracic Oncology.

P2.04-10 Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients

N. Viñolas, B. Massuti, M. Provencio, 2019, Journal of Thoracic Oncology.

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal for ImmunoTherapy of Cancer.

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).

J. Bosch-Barrera, R. Rosell, N. Reguart, 2020, Lung cancer.

Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1

V. Escudero-Vilaplana, A. Insa, I. Sullivan, 2023, Journal of medical economics.

Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients

I. Chirivella, A. Lluch, A. Bosch, 2009, Breast Cancer Research and Treatment.

Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non–Small‐Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery

R. Rosell, M. Santarpia, J. Ramírez, 2017, Clinical lung cancer.

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study.

J. Mate, M. Salido, F. López-Ríos, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation

A. Cervantes, A. Insa, J. Martínez-Jabaloyas, 2021, ESMO Open.

Impact of the COVID-19 Pandemic on a Cancer Fast-Track Programme

B. Bermejo, A. Insa, J. Martínez-Jabaloyas, 2022, Cancer control : journal of the Moffitt Cancer Center.

OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal of Thoracic Oncology.

OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal of Thoracic Oncology.

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

I. Wistuba, N. Viñolas, B. Massuti, 2021, Clinical and translational medicine.

Comprehensive cross‐platform comparison of methods for non‐invasive EGFR mutation testing: results of the RING observational trial

J. Bosch-Barrera, B. Massuti, M. Provencio, 2020, Molecular oncology.

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

E. Felip, J. Bosch-Barrera, J. Palacios, 2021, Cancer medicine.

In the literature: December 2019

A. Cervantes, J. Cejalvo, A. Insa, 2020, ESMO Open.

Comprehensive cross-platform comparison of methodologies for noninvasive EGFR mutation testing: Results of the RING observational trial.

R. Rosell, A. Royuela, C. Camps, 2020 .

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

A Vergnenegre, X. Chen, X. Qian, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial

F. Shepherd, E. Felip, T. Fitzgerald, 2014, Experimental Hematology & Oncology.

P1.09-09 Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients

M. Salido, F. López-Ríos, F. Rojo, 2018, Journal of Thoracic Oncology.

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group).

J. Bosch-Barrera, R. Rosell, N. Reguart, 2018 .

SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)

N. Reguart, R. García-Campelo, J. Zugazagoitia, 2023, Clinical and Translational Oncology.

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

Javier M. Martín-López, J. Bosch-Barrera, N. Reguart, 2023, New England Journal of Medicine.

Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC).

R. Rosell, M. Sánchez-Ronco, M. Provencio, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial (RENO): Efficacy results of oral vinorelbine or etoposide combined with cisplatin in chemo-radiotherapy treatment of locally advanced NSCLC (LA-NSCLC)—SLCG 10/02.

N. Viñolas, M. Provencio, R. Peñas, 2016 .

Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure.

J. Garcia-conde, A. Lluch, E. Díaz-Rubio, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

E. Felip, F. de Marinis, G. Altavilla, 2012, The Lancet. Oncology.

Screening for epidermal growth factor receptor mutations in lung cancer.

L. Paz-Ares, R. Rosell, M. Taron, 2009, The New England journal of medicine.

Combined DNA repair gene single nucleotide polymorphisms (SNPs) in gemcitabine (gem)/cisplatin (cis)-treated non-small-cell lung cancer (NSCLC) patients (p).

R. Rosell, M. Taron, M. Sánchez-Ronco, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

9141 POSTER Phase l/ll Trial of Vorinostat (V) in Combination With Erlotinib (E) in Advanced Non-small Cell Lung Cancer (NSCLC) Patients (pts) With EGFR Mutations After Erlotinib Progression – the TARZO Trial (NCT00503971)

R. Rosell, N. Reguart, C. Rolfo, 2011 .

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

E. Felip, D. Rodríguez-Abreu, L. Nogova, 2024, ESMO open.